Skip to main content
    V

    Viatris Inc (VTRS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $20.74
    -0.08 (-0.38%)

    Market Cap: $23.87B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viatris Inc (VTRS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Viatris (VTRS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Viatris reported EPS of $0.71, above the $0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +4.37%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.62
    Range$0.56 - $0.66
    12 analysts
    Revenue Consensus
    $3.84B
    Range$3.64B - $3.99B
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.63
    Range$0.58 - $0.68
    6 analysts
    EPS Revisions
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.60+6.2%
    60d ago$0.60+5.9%
    30d ago$0.62+2.5%
    7d ago$0.64-0.2%
    Current$0.63
    Revenue Consensus
    $3.60B
    Range$3.53B - $3.67B
    5 analysts

    Next Report

    VTRS has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.8% above the $0.57 reported for the quarter ended Dec 31, 2025.

    VTRS Earnings Call

    The latest VTRS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VTRS beat 29, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $3.75B, down 0.3% from $3.76B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.71$0.64$0.62 - $0.66+10.94%Beat+6.0%101 up, 2 downNov 5, 2026$3.75B
    Jun 30, 2026$0.69$0.62$0.57 - $0.62+11.29%Beat+11.3%81 up, 2 downAug 6, 2026$3.76B
    Mar 31, 2026$0.59$0.50$0.48 - $0.55+18.00%Beat+18.0%81 up, 2 downMay 7, 2026$3.52B
    Dec 31, 2025$0.57$0.52$0.51 - $0.59+9.62%Beat+5.6%80 up, 2 downFeb 26, 2026$3.70B
    Sep 30, 2025$0.67$0.62$0.60 - $0.64+8.06%Beat-10.7%71 up, 1 downNov 6, 2025$3.76B
    Jun 30, 2025$0.62$0.56$0.53 - $0.58+10.71%Beat-10.1%51 up, 0 downAug 7, 2025$3.58B
    Mar 31, 2025$0.50$0.49$0.45 - $0.52+2.04%Beat-25.4%40 up, 1 downMay 8, 2025$3.25B
    Dec 31, 2024$0.54$0.57$0.54 - $0.61-5.59%Miss-12.9%60 up, 1 downFeb 27, 2025$3.53B
    Sep 30, 2024$0.75$0.68$0.64 - $0.71+10.29%Beat-5.1%60 up, 0 downNov 7, 2024$3.75B
    Jun 30, 2024$0.69$0.68$0.65 - $0.70+1.47%Beat-8.0%60 up, 0 downAug 8, 2024$3.80B
    Mar 31, 2024$0.67$0.67$0.64 - $0.700.00%In line-13.0%60 up, 0 downMay 9, 2024$3.66B
    Dec 31, 2023$0.62$0.65$0.57 - $0.70-4.62%Miss-7.5%60 up, 0 downFeb 28, 2024$3.84B
    Sep 30, 2023$0.79$0.74$0.67 - $0.79+6.76%Beat-9.2%70 up, 0 downNov 7, 2023$3.94B
    Jun 30, 2023$0.75$0.71$0.68 - $0.75+5.63%Beat-14.8%71 up, 0 downAug 7, 2023$3.92B
    Mar 31, 2023$0.77$0.70$0.65 - $0.72+10.00%Beat-17.2%80 up, 0 downMay 8, 2023$3.73B
    Dec 31, 2022$0.67$0.72$0.55 - $0.94-6.94%Miss-16.3%111 up, 0 downFeb 27, 2023$3.88B
    Sep 30, 2022$0.87$0.84$0.79 - $0.93+3.57%Beat-12.1%100 up, 1 downNov 7, 2022$4.08B
    Jun 30, 2022$0.88$0.82$0.74 - $0.88+7.32%Beat-10.2%90 up, 1 downAug 8, 2022$4.12B
    Mar 31, 2022$0.93$0.83$0.77 - $0.88+12.05%Beat+1.1%100 up, 0 downMay 9, 2022$4.19B
    Dec 31, 2021$0.80$0.83$0.78 - $0.98-3.61%Miss-25.9%11N/AFeb 28, 2022$4.34B
    Sep 30, 2021$0.99$0.88$0.82 - $0.96+12.50%Beat-24.4%105 up, 0 downNov 8, 2021$4.54B
    Jun 30, 2021$0.98$0.88$0.77 - $0.95+11.36%Beat-11.7%12N/AAug 9, 2021$4.58B
    Mar 31, 2021$0.92$0.80$0.70 - $0.89+15.00%Beat+2.2%12N/AMay 10, 2021$4.43B
    Dec 31, 2020$1.08$1.24$0.88 - $1.79-12.90%Miss-22.9%13N/AMar 1, 2021$3.62B
    Sep 30, 2020$1.31$1.16N/A+12.93%Beat+12.0%N/AN/ANov 6, 2020$2.97B
    Jun 30, 2020$1.11$0.98N/A+13.27%Beat+7.8%N/AN/AAug 6, 2020$2.73B
    Mar 31, 2020$0.90$0.87N/A+3.45%Beat+9.8%N/AN/AMay 11, 2020$2.62B
    Dec 31, 2019$1.40$1.28N/A+9.38%Beat+7.7%N/AN/AFeb 27, 2020$3.19B
    Sep 30, 2019$1.17$1.14N/A+2.63%Beat-6.4%N/AN/ANov 5, 2019N/A
    Jun 30, 2019$1.03$0.95N/A+8.42%Beat-3.7%N/AN/AJul 29, 2019N/A
    Mar 31, 2019$0.82$0.79N/A+3.80%Beat-14.6%N/AN/AMay 7, 2019$2.50B
    Dec 31, 2018$1.30$1.36N/A-4.41%Miss-9.1%N/AN/AFeb 26, 2019$3.08B
    Sep 30, 2018$1.25$1.19N/A+5.04%Beat+13.6%N/AN/ANov 5, 2018$2.86B
    Jun 30, 2018$1.07$1.22N/A-12.30%Miss-2.7%N/AN/AAug 8, 2018$2.81B
    Mar 31, 2018$0.96$0.96N/A0.00%In line+3.2%N/AN/AMay 9, 2018$2.68B
    Dec 31, 2017$1.43$1.41N/A+1.42%Beat-8.9%N/AN/AFeb 28, 2018$3.24B
    Sep 30, 2017$1.10$1.20N/A-8.33%Miss-20.3%N/AN/ANov 6, 2017$2.99B
    Jun 30, 2017$1.10$1.16N/A-5.17%Miss-5.2%N/AN/AAug 9, 2017$2.96B
    Mar 31, 2017$0.93$0.92N/A+1.09%Beat+22.4%N/AN/AMay 10, 2017$2.72B
    Dec 31, 2016$1.57$1.42N/A+10.56%Beat+28.7%N/AN/AMar 1, 2017$3.27B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.36, down 10.9% from the year before. It was $4.87 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.36-10.9%
    Dec 31, 2024$2.65-9.6%
    Dec 31, 2023$2.93-12.5%
    Dec 31, 2022$3.35-9.2%
    Dec 31, 2021$3.69-16.1%
    Dec 31, 2020$4.40N/A
    Dec 31, 2019$4.42-3.5%
    Dec 31, 2018$4.58N/A
    Dec 31, 2017$4.56-6.4%
    Dec 31, 2016$4.87N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,03515
    2026Q2Jun 30, 20268,28414
    2026Q1Mar 31, 20266,33814
    2025Q4Dec 31, 20257,80915
    2025Q3Sep 30, 20255,68912
    2025Q2Jun 30, 20255,82811
    2025Q1Mar 31, 20255,88711
    2024Q4Dec 31, 20247,64912

    2026Q3 Earnings Call

    Opening remarks

    William Szablewski Head of Capital Markets Good morning, everyone. Welcome to our Q3 2026 earnings call. With us today is our CEO, Scott Smith; Interim CFO, Paul Campbell; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures. When discussing 2026 actual or reported results, we will be making certain comparisons to 2025 actual or reported results on an operational basis, which excludes the impact of foreign currency rates. When comparing our 2026 actual reported results to our expectations, we are making comparisons to our 2026 financial guidance. With that, I'll hand the call over to our CEO, Scott Smith.

    Scott Smith CEO Good morning, everyone. We're pleased with our strong third quarter performance, which reflects continued momentum across our businesses. As we've been saying, we believe we've entered a new phase of sustained growth for Viatris. The disciplined execution of the strategy we outlined earlier this year is translating into results. During the third quarter, we delivered total revenues of $3.75 billion, adjusted EBITDA of $1.2 billion and adjusted EPS of $0.71 per share. Through the first 9 months of the year, total revenues grew 2%, adjusted EBITDA grew 6% and adjusted EPS grew 8% operationally compared to the prior year, demonstrating continued progress toward our long-term financial targets. Given our performance and expectations for continued momentum in the fourth quarter, we are narrowing our financial guidance ranges and once again raising the midpoint for all key financial metrics. Paul will provide more details shortly. Now let me walk through a few highlights for the quarter. Our base business continues to deliver solid results, reflecting the strength and durability of our portfolio. We're pleased with our performance in North America and Greater China, where we continue to see meaningful growth. In North America, growth is accelerating as our portfolio mix shifts toward more durable, higher-margin products and complex generics, supported by strong demand for our estradiol patches and new product revenue from our recent injectable launches. We are pleased to have launched Gwyn Lo, our low-dose contraceptive patch in the U.S. in October. In Greater China, growth continues to be driven by strong demand for our cardiovascular portfolio and the strength of our established brands.

    Frequently Asked Questions About VTRS

    When is Viatris's next earnings date?

    Viatris's next earnings report is expected for Feb 24, 2027.

    Did VTRS beat earnings estimates last quarter?

    Yes. Viatris reported EPS of $0.71 for the quarter ended Sep 30, 2026, above the $0.64 estimate, a 10.94% surprise.

    What EPS do analysts expect from VTRS next quarter?

    The consensus EPS estimate for Viatris for the quarter ending Dec 31, 2026 is $0.62 from 12 analysts, with estimates from $0.56 to $0.66.

    How often does VTRS beat earnings estimates?

    Viatris beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.13%.